Document Type
Plan B - Open Access
Award Date
2023
Degree Name
Master of Science (MS)
Department
Biology and Microbiology
First Advisor
Greg Heiberger
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is the most frequently mutated (95%) 5exocrine pancreatic cancers. Patients with PDAC are also the least likely to survive more than 5 years with only 8% overall survivability. The median survival for patients with distant metastasis is less than one year. Most pancreatic ductal adenocarcinoma occurs in the pancreatic head, and the remainder can be found within the body (5% to 15%) or tail (10% to 15%) (14). This extremely aggressive cancer has an increasingly large metastatic dissemination rate to surrounding organs such as the liver, lung, and peritoneum, or can be seen as distant metastases in the brain and bone. These widespread and fatal metastases account for 70% of PDAC cancer related deaths due to end stage diagnosis or dissemination early on in the disease that has spread to other sites.
Publisher
South Dakota State University
Rights
© 2023 Melissa J Moisan
Recommended Citation
Moisan, Melissa J., "Pancreatic Ductal Adenocarcinoma and New Treatments in Development" (2023). Biology and Microbiology Graduate Students Plan B Research Projects. 45.
https://openprairie.sdstate.edu/biomicro_plan-b/45